GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ChemoMetec AS (FRA:CHY) » Definitions » Debt-to-EBITDA

ChemoMetec AS (FRA:CHY) Debt-to-EBITDA : 0.03 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is ChemoMetec AS Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ChemoMetec AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.42 Mil. ChemoMetec AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.63 Mil. ChemoMetec AS's annualized EBITDA for the quarter that ended in Dec. 2024 was €38.18 Mil. ChemoMetec AS's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ChemoMetec AS's Debt-to-EBITDA or its related term are showing as below:

FRA:CHY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02   Med: 0.16   Max: 1.42
Current: 0.03

During the past 13 years, the highest Debt-to-EBITDA Ratio of ChemoMetec AS was 1.42. The lowest was 0.02. And the median was 0.16.

FRA:CHY's Debt-to-EBITDA is ranked better than
94.55% of 440 companies
in the Medical Devices & Instruments industry
Industry Median: 1.425 vs FRA:CHY: 0.03

ChemoMetec AS Debt-to-EBITDA Historical Data

The historical data trend for ChemoMetec AS's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoMetec AS Debt-to-EBITDA Chart

ChemoMetec AS Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.02 0.03 0.03 0.02

ChemoMetec AS Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.02 0.03

Competitive Comparison of ChemoMetec AS's Debt-to-EBITDA

For the Medical Devices subindustry, ChemoMetec AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChemoMetec AS's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ChemoMetec AS's Debt-to-EBITDA falls into.


;
;

ChemoMetec AS Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ChemoMetec AS's Debt-to-EBITDA for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.426 + 0.131) / 25.99
=0.02

ChemoMetec AS's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.418 + 0.625) / 38.178
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2024) EBITDA data.


ChemoMetec AS  (FRA:CHY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ChemoMetec AS Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ChemoMetec AS's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoMetec AS Business Description

Traded in Other Exchanges
Address
Gydevang 43, Allerod, DNK, 3450
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.